Results 41 to 50 of about 2,004 (157)

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%

American Journal of Hematology, Volume 101, Issue 9, Page 2311-2328, September 2026.
ABSTRACT The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5‐year French nation‐wide multicenter prospective observational study.
Orianne Wagner‐Ballon, Anne‐Catherine Lhoumeau, Anna Raimbault, Camille Debord, Jean‐Philippe Vial, Valérie Soenen, Mélanie Pannetier, Edouard Bonneville, Elsa Bera, Caroline Bret, Nicolas Chapuis, Véronique Latger‐Cannard, Caroline Mayeur‐Rousse, Véronique Harrivel, François Vergez, Marie Loosveld, Juliette Vo Xuan, Stéphanie Mathis, Gérard Socié, Flore Sicre de Fontbrune, Régis Peffault de Latour, Bernard Drenou, Agathe Debliquis, Magali Le Garff‐Tavernier, on behalf of the French PNH working group CytHem‐HPN, Thomas Boyer, Mikaël Roussel, Marie Guillon, Sabrina Bouyer, Isabelle Kittler, Franck Geneviève, Julien Guy, Sophie Brun, Claude Capron, Sébastien Lachot, Francine Garnache‐Ottou, Richard Veyrat‐Masson, Corine Brunet, Caren Brumpt, Ludovic Lhermitte. Finally, Louis Terriou, Nicolas Blin   +41 more
wiley   +1 more source

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

Thrombosis Journal, 2021
Background In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.
Sufana Shikdar, Azra Borogovac, Elabdallah Mohamad, Mohamad Khawandanah   +3 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD

Annals of Clinical and Translational Neurology, Volume 13, Issue 7, Page 1488-1492, July 2026.
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam   +4 more
wiley   +1 more source

Diagnostic Challenges and Clinical Management of Area Postrema Syndrome: A Case Report on Persistent Nausea and Vomiting

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Area postrema syndrome (APS) is a rare neurological syndrome that presents a significant diagnostic challenge due to its nonspecific clinical manifestations, most commonly persistent nausea and vomiting, which frequently lead to initial misdiagnosis as a gastrointestinal disorder.
Andreea‐Gabriela Manole, D. Ion, Alexandra Bolocan, O. Andronic, D. N. Păduraru   +4 more
wiley   +1 more source

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun‐ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj   +15 more
wiley   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source